Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
ConclusionsA single SABR session was feasible and associated with low morbidity in this cohort. Over one-third of patients did not progress and were free from ADT at 2-yr. QoL measures were maintained with this treatment strategy.Patient summaryThis clinical trial investigated single treatment stereotactic radiotherapy for low volume advanced prostate cancer. The approach was found to be safe with avoidance of hormone therapy in almost half of the participants at 2 yr.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Acidul | Cancer | Cancer & Oncology | Clinical Trials | CT Scan | Fluoride | Hormonal Therapy | Hormones | Legislation | Orthopaedics | PET Scan | Prostate Cancer | Sodium | Sodium Fluoride | Toxicology | Urology & Nephrology